Disc Medicine FY2024 EPS Estimate Raised by Lifesci Capital

Disc Medicine, Inc. (NASDAQ:IRON) – Lifesci Capital lifted their FY2024 EPS estimates for shares of Disc Medicine in a research note issued on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now forecasts that the company will post earnings of ($3.92) per share for the year, up from their prior estimate of ($4.33). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share. Lifesci Capital also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.94) EPS.

A number of other brokerages have also recently commented on IRON. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $66.00 to $110.00 in a report on Monday, November 4th. Wedbush reaffirmed an “outperform” rating and issued a $83.00 target price (up from $75.00) on shares of Disc Medicine in a report on Tuesday. Jefferies Financial Group initiated coverage on Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Scotiabank boosted their price objective on Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 5th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Disc Medicine has a consensus rating of “Buy” and an average target price of $85.80.

Disc Medicine Stock Down 3.8 %

NASDAQ IRON opened at $60.67 on Friday. The company has a 50-day moving average price of $51.02 and a 200-day moving average price of $44.75. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds have recently modified their holdings of the stock. Atlas Venture Life Science Advisors LLC increased its holdings in Disc Medicine by 9.7% in the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company’s stock valued at $113,101,000 after acquiring an additional 222,223 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in shares of Disc Medicine by 123.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after purchasing an additional 969,834 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of Disc Medicine by 53.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock worth $46,119,000 after buying an additional 357,730 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Disc Medicine by 59.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock valued at $58,788,000 after buying an additional 353,382 shares during the last quarter. Finally, Logos Global Management LP purchased a new position in Disc Medicine during the 2nd quarter valued at approximately $41,690,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Insider Buying and Selling

In other Disc Medicine news, Director William Richard White sold 7,136 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 7,538 shares of company stock valued at $437,875. Corporate insiders own 4.24% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.